Singapore’s $10 Million Grant Sets Timeline for Arcturus Therapeutics
San Diego‑based Arcturus Therapeutics received the first tranche of a $10 million grant from Singapore’s Economic Development Board on March 9, depositing $3 million into its accounts. The funds are earmarked for GMP‑grade reagents, animal toxicology studies and small‑scale production runs. The award came only eight weeks after China released the viral genome sequence, a period when local transmission was rising across Southeast Asia.
Singapore sought a contingency plan that would not rely on the large European vaccine manufacturers and could be produced domestically if global supply chains were disrupted. Arcturus proposed a self‑replicating RNA construct.
Pre‑clinical data show that this platform yields roughly thirty times more viral antigen per microgram of RNA than conventional messenger RNA. That advantage translates into smaller vials, faster manufacturing batches and a lower cost per dose—considerations that matter for a nation aiming to immunise about six million residents and guest workers. Joseph Payne, Arcturus’s chief executive, briefed investors on March 11, explaining that the company’s STARR technology keeps the body’s innate immune sensors activated, eliminating the need for a booster shot.
He stated, “What we bring to the equation here is a single‑shot solution and a 30‑fold improvement in dosing. That is why Singapore selected us.” The grant is released in milestone‑linked tranches; it is not an open‑ended check.
Under the agreement Singapore retains ownership of any eventual product while granting Arcturus worldwide commercialisation rights. Arcturus will collaborate with Duke‑NUS Medical School and the National University of Singapore to advance the candidate from laboratory work to clinical testing. For Singapore the deal addresses supply‑chain security and speed.
A nimble, self‑amplifying RNA platform can be manufactured quickly inside the country’s own biotech facilities, avoiding dependence on overseas shipments or foreign factories that might cease operation during a crisis. For Arcturus the infusion provides both cash and credibility; a $10 million commitment from a sovereign wealth fund signals confidence and imposes a strict timeline pressure—missing a milestone would halt further payments.
The arrangement also reflects a broader shift in vaccine funding, with governments increasingly backing small biotechs that traditionally received support only from large pharmaceutical firms. By choosing a California startup over established players, Singapore’s Economic Development Board bet on a technology promising a single injection, reduced raw‑material use per dose and rapid scale‑up. Animal studies are encouraging, but such data do not always predict human outcomes; the decisive test will arise when the candidate enters clinical trials. Singapore’s funding gets Arcturus to that stage; subsequent success will depend on the science itself.
Other governments are observing the outcome. A positive result could spur similar partnerships, while a setback would prompt a search for alternatives.
Singapore has hedged its risk by supporting multiple approaches; this Arcturus award forms one component of a larger portfolio. The initial $3 million has already been allocated, and the next tranche will be released upon achievement of the next development milestone. Arcturus now answers to Singapore’s Economic Development Board, to its academic partners Duke‑NUS and NUS, and ultimately to the six million people awaiting a vaccine.
